FILE PHOTO: The exterior of the European Medicines Agency is seen in Amsterdam, Netherlands, December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo
(Reuters) – The European medicines regulator said on Monday it would hold a meeting this week on the information gathered into whether the AstraZeneca COVID-19 vaccine contributed to thromboembolic events in those inoculated.
While its investigation is ongoing, the European Medicines Agency remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19 outweigh the risks of side effects. (bit.ly/3trmufB)
Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak Dasgupta
Our Standards: The Thomson Reuters Trust Principles.
Amazon secured a key early win as a federal judge blocked New York from enforcing…
The Enthuse Foundation has revealed the finalists for its 7th Annual Women Founders Pitch Competition,…
The Marcus Evans 2nd Edition Model Risk Management, Canada conference taking place in Toronto, Canada…
Economists say Shanghai is strengthening its role as China’s reform engine, accelerating innovation and global…
U.S. shoppers are set to spend nearly $80 billion this Black Friday and Cyber Monday,…
Waiken has unveiled a US$450 million investment plan through 2031 to strengthen its entertainment and…